Tough criticisms rise as biotech matures
Lawmakers point to high drug prices, crop worries
Thirty years ago, the business of biotechnology amounted to a handful of scientists, a few brave investors, and a bold, if unproven, idea: By tweaking genes in a lab, you could transform the process of making drugs. (Full article: 1133 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
